Data / Form D filings / Unity Biotechnology, Inc.
Unity Biotechnology, Inc.: Form D filings
Unity Biotechnology, Inc., a pharmaceuticals company in Brisbane, CA, filed 6 Form D notices with the SEC between 2009 and 2018. The latest, on March 27, 2018, reports $55 million sold of a $60 million offering to 27 investors.
Find out what Unity Biotechnology, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3280 BAYSHORE BOULEVARD, Brisbane, CA, 94005
- Phone
- (650) 416-1192
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1463361
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 27, 2018 | New notice | $60,000,000 | $55,049,948 | $4,950,052 | 27 | Mar 15, 2018 | sec.gov |
| Aug 21, 2017 | Amendment | $177,598,051 | $151,230,099 | $26,367,952 | 38 | Oct 14, 2016 | sec.gov |
| Dec 1, 2016 | New notice | $128,278,051 | $108,320,117 | $19,957,934 | 26 | Oct 14, 2016 | sec.gov |
| Jul 15, 2013 | New notice | $6,083,265 | $2,041,555 | $4,041,710 | 4 | Jul 3, 2013 | sec.gov |
| May 5, 2009 | New notice | $1,000,000 | $250,000 | $750,000 | 1 | Apr 23, 2009 | sec.gov |
| May 5, 2009 | New notice | $500 | $500 | $0 | 2 | Apr 22, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kristina E. Burow | Director | |
| Dan E. Marquess | Executive Officer | |
| Keith E. Leonard | Executive Officer, Director | |
| Tamara E. Tompkins | Executive Officer | |
| Paul E. Berns | Director | |
| Bob E. Goeltz | Executive Officer | |
| Robert E. Nelsen | Director | |
| Camille E. Samuels | Director | |
| Jamie E. Dananberg | Executive Officer | |
| Nathaniel E. David | Executive Officer, Director | |
| Graham E. Cooper | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Mar 26, 2018 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Unity Biotechnology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.